Navigation Links
Upsher-Smith Debuts Positive Results From Global Phase 3 Study Evaluating USL255 (extended-release topiramate) In Epilepsy Patients With Refractory Partial-Onset Seizures
Date:12/9/2013

MAPLE GROVE, Minn., Dec. 9, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today presented results from its global Phase 3 (PREVAIL) study of USL255 (extended-release topiramate), showing that the investigational drug met its primary and secondary endpoints for efficacy and demonstrated favorable safety and tolerability in epilepsy patients with refractory partial-onset seizures (POS). The data were presented for the first time at the American Epilepsy Society's (AES) 67th Annual Meeting in Washington, DC, December 6-10, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130520/NY17281LOGO)

USL255 is a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK) profile. Upsher-Smith's New Drug Application for USL255 has been accepted for review by the U.S. Food and Drug Administration (FDA).

Findings presented at the meeting showed that USL255 was associated with a significantly greater median percent reduction in weekly POS frequency compared with placebo (39.5% vs 21.6%, P<0.001) after 11 weeks of treatment. The majority of treatment-emergent adverse events (TEAEs) reported were mild to moderate in intensity and generally resolved over time.  Individual neurocognitive adverse events were each observed at incidence rates of 2.4 percent or less in patients taking USL255.  Although ongoing, to-date 96.8 percent of patients who completed the double-blind portion of PREVAIL elected to continue in a year-long, open-label extension study of USL255.

"Topiramate is a well-known, effective agent for the treatment of a variety of seizure disorders, but many patients experience challenging cognitive side effects whil
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment
2. Upsher-Smith To Present New Research On USL255 (Extended-Release Topiramate) At 2013 American Epilepsy Society Annual Meeting
3. Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting
4. Upsher-Smith Announces Development Agreement With Lundbeck
5. Upsher-Smith Announces Commercial Availability Of Morphine Sulfate ER Capsules
6. Upsher-Smith Teams Up With Epilepsy Foundation Of Minnesota For 2013 Stroll For Epilepsy
7. Upsher-Smith Announces Patient Enrollment In Open-label Safety Study Of USL261 (Intranasal Midazolam) For Rescue Treatment Of Seizure Clusters In Epilepsy
8. Upsher-Smith Is Honored With Prestigious Industry Award For Leadership And Innovation
9. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
10. Upsher-Smith Introduces Newly Redesigned Corporate Website
11. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Calif. , Aug. 31, 2015 ... flow cytometry is experiencing a rise in active ... demand in underdeveloped nations to quantitate CD4 cell ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... of the Global Flow Cytometry Market ( http://www.frost.com/nf0e ...
(Date:8/31/2015)... , Aug. 31, 2015  The departments of Drug ... today at Gaudenzia Concept 90 to raise awareness for ... crisis in Pennsylvania and help ... focus on recovery through the Building Bridges to ... are dying every day to a disease that is ...
(Date:8/31/2015)... , Aug. 31, 2015  Diplomat Pharmacy, Inc. (NYSE: ... that Phil Hagerman , Chairman & CEO, and ... conferences. Mr. Hagerman and Mr. Whelan are ... in Boston on Wednesday, September 9, ... Mr. Whelan are also scheduled to participate in the Robert ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... OrbusNeich today announced that six-month clinical follow-up data show the safety ... balloon (Sequent Please®, B.Braun) followed by implantation of the company,s Genous ... , , , ... investigator-initiated, single center, all-comers POTENT ( P aclitaxel-eluting ball O on ...
... Pfizer Inc. (NYSE: PFE ) announced today that based ... be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for ... States and that it will be voluntarily withdrawing the new drug ... , , ...
Cached Medicine Technology:Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 2Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... In an ... from the Plastic and Reconstructive Surgery Global Open Journal that discusses the future of ... article discussed how, in the future, customized implants, prosthetics, and other 3-D printed tools ...
(Date:8/31/2015)... ... August 31, 2015 , ... David L. Chalnick, M.D., ... of the first doctors in the area to perform minimally invasive hip replacement ... impressive: faster recovery, decreased immediate and long-term pain, and an accelerated return to ...
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... years as an “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical ... general orthopedics and traumatic injuries to the entire musculoskeletal system, excluding the spine. , ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... diagnostic services, and others—to hold down costs? , In a commentary for ... of HealthReveal, presents the concept of “clinical efficacy,” which would bind parties together ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... ... the 2015 ABBY Awards, at the 16th Innovations in Healthcare(SM) Awards Event ... Adaptive Business Leaders (ABL) Organization , recognizes innovative organizations and individuals who ...
Breaking Medicine News(10 mins):Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8
... 2 Rochester Medical Corporation (Nasdaq: ROCM ) ... 31, 2008.The Company reported sales of $8,436,000 for the current ... year. It also reported net income of $54,000 or ... or $.02 per diluted share for the first quarter of ...
... Calif., Feb. 2 Digirad Corporation (Nasdaq: ... and personnel and equipment leasing services that improve patient ... it has sold the assets related to three northern ... with Rancho Santa Fe, Calif.-based MD Office Solutions calls ...
... More exposure meant more symptoms, study found , , MONDAY, ... hours watching television are at higher risk for depression ... significantly greater odds of being depressed seven years later, ... television viewed, according to a report involving more than ...
... for Quality,Assurance (NCQA) has awarded Unison Health Plan of ... program through December 2011. The plan serves,more than ... is based on how well a health plan ensures ... the health,plan,s core systems and processes, but also the ...
... are heavy users of marijuana are more likely ... to a new study. Pediatric researchers found abnormalities ... regions involved in memory, attention, decision-making, language and ... concern because adolescence is a crucial period for ...
... Post-Katrina flooded homes may contain harmful levels of ... mold films, and aerosols may also have exposed residents, ... without the need for direct skin contact, according to ... (Volume 26, Number 3) of Environmental Engineering Science, a ...
Cached Medicine News:Health News:Rochester Medical Reports First Quarter Results 2Health News:Rochester Medical Reports First Quarter Results 3Health News:Rochester Medical Reports First Quarter Results 4Health News:Rochester Medical Reports First Quarter Results 5Health News:Rochester Medical Reports First Quarter Results 6Health News:Rochester Medical Reports First Quarter Results 7Health News:Rochester Medical Reports First Quarter Results 8Health News:Digirad Corporation Sells Northern California Service Hubs 2Health News:Teen TV Time Tied to Adult Depression 2Health News:Teen TV Time Tied to Adult Depression 3Health News:Unison Health Plan of Ohio Accredited by NCQA 2Health News:Heavy marijuana use may damage developing brain in teens, young adults 2Health News:Newly Described Contaminant Sources in Katrina-Flooded Homes Pose Health Risks 2
... When myocardial infarction is suspected, ... sensitive rapid assay allows rapid ... troponin T from a single ... result is available within minutes ...
The Polygraf ID multi-parametric recorder works with POLYGRAM NET analysis software to create a unique interface that combines web-style navigation, graphical presentation and intuitive design to del...
... the industry standard high intensity 300 Watt Xenon ... price. A universal turret on the front panel ... Olympus, Storz, ACMI/Circon and Wolf cable connectors., ,Front ... timer. The White Sun will quickly illuminate at ...
... is intended for determination of human NGAL ... tissue extracts or culture media., NGAL (neutrophil ... urine, as early as 2 hours after ... processes. NGAL expression in plasma or urine ...
Medicine Products: